Kathleen M. Tornatore

Kathleen M. Tornatore

Auto-generated profile, based on publicly available information

Kathleen M. Tornatore

Immunosuppressive Pharmacology Research Program, Clinical and Translational Therapeutics, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2018 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
OCOlivia Campagne
Olivia Campagne
DMDonald E. Mager
Donald E. Mager
KTKathleen M. Tornatore
Kathleen M. Tornatore

18 May 2018 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
OCOlivia Campagne
Olivia Campagne
DMDonald E. Mager
Donald E. Mager
DBDaniel Brazeau
Daniel Brazeau
RVRocco C. Venuto
Rocco C. Venuto
KTKathleen M. Tornatore
Kathleen M. Tornatore

16 December 2014 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
KTKathleen M. Tornatore
Kathleen M. Tornatore
CMCalvin J. Meaney
Calvin J. Meaney
GWGregory E. Wilding
Gregory E. Wilding
SCShirley S. Chang
Shirley S. Chang
AGAijaz Gundroo
Aijaz Gundroo
RVRocco C. Venuto
Rocco C. Venuto

1 February 2022 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
PDF file
KTKathleen M. Tornatore
Kathleen M. Tornatore
CMCalvin J. Meaney
Calvin J. Meaney
KAKristopher Attwood
Kristopher Attwood
DBDaniel A. Brazeau
Daniel A. Brazeau
GWGregory E. Wilding
Gregory E. Wilding
RVRocco C. Venuto
Rocco C. Venuto
Study Objective: This study investigated race and sex differences in tacrolimus pharmacokinetics and pharmacodynamics in stable kidney transplant recipients.Design and Setting: A cross‐sectional, open‐label, single center, 12‐h pharmacokinetic‐pharmacodynamic study was conducted. Tacrolimus pharmacokinetic parameters included area under the concentration‐time curve (AUC0–12), AUC0–4, 12‐h troughs (C12 h), maximum concentrations (Cmax), oral clearance (Cl), with dose‐normalized AUC0–12, troughs, and Cmax with standardized adverse effect scores. Statistical models were used to analyze end points with individual covariate‐adjustment including clinical factors, genotypic variants CYP3A5*3, CYP3A5*6, CYP3A5*7(CYP3A5*3*6*7) metabolic composite, and ATP binding cassette gene subfamily B member 1 (ABCB1) polymorphisms.Patients: 65 stable, female and male, Black and White kidney transplant recipients receiving tacrolimus and mycophenolic acid ≥6 months post‐transplant were evaluated.Measurements and Main Results: Black recipients exhibited higher tacrolimus AUC0–12 (Race: p = 0.005), lower AUC* (Race: p < 0.001; Race × Sex: p = 0.068), and higher Cl (Race: p < 0.001; Sex: p = 0.066). Greater cumulative (Sex: p < 0.001; Race × Sex: p = 0.014), neurologic (Sex: p = 0.021; Race × Sex: p = 0.005), and aesthetic (Sex: p = 0.002) adverse effects were found in females, with highest scores in Black women. In 84.8% of Black and 68.8% of White patients, the target AUC0–12 was achieved (p = 0.027). In 31.3% of White and 9.1% of Black recipients, AUC0–12 was <100 ng‧h/ml despite tacrolimus troughs in the target range (p = 0.027). The novel CYP3A5*3*6*7 metabolic composite was the significant covariate accounting for 15%–19% of tacrolimus variability in dose (p = 0.002); AUC0–12 h* (p < 0.001), and Cl (p < 0.001).Conclusions: Tacrolimus pharmacokinetics and adverse effects were different among stable kidney transplant recipient groups based upon race and sex with interpatient variability associated with the CYP3A5*3*6*7 metabolic composite. More cumulative, neurologic, and aesthetic adverse effects were noted among females. Tacrolimus regimens that consider race and sex may reduce adverse effects and enhance allograft outcomes by facilitating more patients to achieve the targeted AUC0–12 h.

10 November 2018 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
OCOlivia Campagne
Olivia Campagne
DMDonald E. Mager
Donald E. Mager
DBDaniel Brazeau
Daniel Brazeau
RVRocco C. Venuto
Rocco C. Venuto
KTKathleen M. Tornatore
Kathleen M. Tornatore

3 July 2013 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
KTKathleen M. Tornatore
Kathleen M. Tornatore
DBDaniel Brazeau
Daniel Brazeau
KDKiran Dole
Kiran Dole
RDRyan Danison
Ryan Danison
GWGregory Wilding
Gregory Wilding
RVRocco C. Venuto
Rocco C. Venuto